Panelists discuss the promising results of the BOND-3 trial evaluating intravesical cretostimogene for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), highlighting its high complete ...

Panelists discuss emerging immunotherapy strategies for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), particularly the combination of BCG with systemic checkpoint inhibitors, noting ...

Key Takeaways ART-101, a novel PSMA-targeting small molecule, received FDA IND clearance for mCRPC treatment, enabling a phase 1 trial launch. Preclinical studies show ART-101 has higher tumor uptake ...

The device was previously approved in March 2019 3 for patients with BPH with prostate volumes ranging from 30 cm 3 to 80 cm 3. “The recent FDA-cleared indication expansion has increased the maximum ...

Data also showed that IPSS and M-ISI bother scores were lower in the OTA cohort. Specifically, the mean IPSS bother score was 3.0 in the OTA arm vs 3.7 in the control arm at 3 months. Further, the ...

Darolutamide was approved in this indication in the US in June 2025. 2 With this approval, darolutamide became the first androgen receptor inhibitor to be FDA approved for use in patients with mHSPC ...

In this episode of Pearls and Perspectives, host Amy Pearlman, MD, is joined by Joshua R. Gonzalez, MD —a board-certified urologist and sexual medicine specialist based in Los Angeles, California—for ...

Key Takeaways Apalutamide showed a significant survival advantage over abiraterone and enzalutamide in mCSPC, with a 26% and 23% reduction in mortality risk, respectively. Real-world data are ...

The investigators found a clear, dose-response relationship between patient-reported incontinence severity and the subsequent use of incontinence interventions such as artificial sphincters or bulking ...

The iSNM system is intended to provide an alternative to traditional SNM for these patients. According to Neuspera, “A smart, miniaturized neurostimulator is implanted near the sacral nerve, and ...

The median duration of the procedure was 220 minutes. Among the 9 patients treated, the median reduction in volume of stone burden was 98% per CT scan at POD30. Grade 1 and 2 adverse events (AEs) were ...

Improving Clinical Trial Diversity Key Themes: A multistakeholder approach is required (patients, communities, clinicians, payers, industry). Community outreach initiatives are essential for building ...